Results of Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in Kidney Transplant Recipients

Updated: May 21

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients


Download the presentation below.

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer
.pdf
Download PDF • 4.14MB

 

About TRACT Therapeutics

TRACT Therapeutics, Inc. is a clinical stage biotechnology company developing a novel therapeutic approach to restoring immune balance in organ transplantation and autoimmune disease. Its proprietary platform technology, using autologous polyclonally expanded regulatory Tcells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, PhD and his research colleagues. TRACT has recently received FDA approval to initiate a Phase 2 trial with Trigs in kidney recipients.


This press release contains forwardlooking statements that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements related to clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward looking statements.

Recent Posts

See All